Abstract
A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine Endorsed by the American College of Emergency Physicians In general, use of cardiac RNI for diagnosis and risk assessment in intermediate- and high-risk patients with coronary artery disease (CAD) was viewed favorably, while testing in low-risk patients, routine repeat testing, and general screening in certain clinical scenarios were viewed less favorably. Given the iterative nature of the process, readers are counseled not to compare too closely individual appropriate use ratings among modalities rated at different times over the past 2 years. Since this process is iterative and evolving, readers are counseled that individual appropriate use ratings among modalities rated at different times over the past 2 years may not be consistent.\n Manesh R. Patel None None None None None None Dr. Eric D. Peterson None None None Bristol-Myers Squibb/Sanofi Aventis Merck Schering-Plough St. Jude None None Dr. Michael J. Wolk None None None None None None Cardiac Radionuclide Imaging Appropriate Use Criteria Indication Reviewers Dr. James Arrighi None None None None None None Dr. Robert O. Bonow Bristol-Myers Squibb Medical Imaging Edwards Lifesciences None None None None None Dr. Lee A. Fleisher None None None None None Preoperative potassium Preoperative potassium level Dr. Julius M. Gardin None CV Therapeutics Pfizer Takeda None Merck None None Dr. Raymond J. Gibbons Cardiovascular Clinical Studies (WOMEN study) Consumers Union TIMI 37A None None Kai Pharmaceuticals King Pharmaceuticals Radiant Medical TargeGen Ther Ox None None Dr. John A. Gillespie None None None None None None Dr. Bennett S. Greenspan None None None None None None Dr. Rory Hachamovitch Bristol-Myers Squibb Medical Imaging GE Healthcare None Astellas Bracco Diagnostics GE Healthcare Siemens None None Dr. Warren R. Janowitz None None None None None None Dr. Christopher M. Kramer Siemens None None Astellas GlaxoSmithKline Merck Siemens None None Dr. Michael H. Picard Acusphere None None Edwards Lifesciences None None Dr. Michael Poon None None None None None None Dr. Miguel A. Quinones None None None None None Diet pills and valve disease Dr. Raymond F. Stainback None None None None None None Dr. Mark I. Travin None None None None None Adding exercise to pharmacologic stress ECG stress testing and ordering nuclear studies Dr. Samuel Wann None None None None None None Dr. R. Parker Ward None None None Pfizer None None Dr. Neil J. Weissman Takeda Wyeth None None Acusphere Arena Pharmaceutical ATS Biotronik Boston Scientific Edwards Lifesciences Lipid Science Point Biomedical Sorin Carbomedics Spectranetics St. Jude Zilver None Anorexic agents Dr. Jack A. Ziffer Tyco Healthcare None CV Therapeutics Spectrum Dynamics Bristol-Myers Squibb CV Therapeutics None None Dr. William A. Zoghbi None None None None None None * ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM CARDIAC RADIONUCLIDE IMAGING APPROPRIATE USE CRITERIA WRITING GROUP, TECHNICAL PANEL, TASK FORCE, AND INDICATION REVIEWERS--RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (IN ALPHABETICAL ORDER) This table represents the relevant relationships of committee members with industry and other entities that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process.
